Abstract
Background and purpose: Miller Fisher syndrome (MFS), a variant of Guillain-Barré Syndrome (GBS), could be underestimated in evaluations of its adverse events (AEs) following COVID-19 vaccination. We aimed to identify and characterize MFS following COVID-19 vaccination.
Materials and methods: Relevant studies reported on during the COVID-19 pandemic were identified in the MEDLINE, Embase, and other databases.
Results: Nine cases of MFS following COVID-19 vaccination from various regions were included. Unlike MFS following COVID-19 infection, patients with MFS following COVID-19 vaccination frequently presented with anti-GQ1b antibody positivity (44%, 4/9). Unlike GBS following COVID-19 vaccination, only two of nine (22%) cases of MFS following COVID-19 vaccination had developed after viral-vector-related vaccine administration.
Conclusions: Miller Fisher syndrome following COVID-19 vaccination seems to have a different pathophysiology from MFS following COVID-19 infection and GBS following COVID-19 vaccination. This neurological syndrome with a rare incidence and difficulty in diagnosis should be considered an AE of COVID-19 vaccination.
Keywords: COVID-19 vaccine; Guillain-Barré syndrome; adverse effects; miller Fisher syndrome; systematic review.
【저자키워드】 COVID-19 vaccine, systematic review, adverse effects, Miller fisher syndrome, Guillain-barrè syndrome, 【초록키워드】 COVID-19, antibody, COVID-19 pandemic, variant, Diagnosis, systematic review, Region, COVID-19 vaccination, COVID-19 infection, pathophysiology, adverse event, Patient, incidence, neurological, syndrome, material, Fisher, Fisher syndrome, vaccine administration, Miller, identify, reported, nine, AEs, the MEDLINE, 【제목키워드】 COVID-19,